[go: up one dir, main page]

MX2011008868A - Derivados de tetrahidronaftalen-2-ol. - Google Patents

Derivados de tetrahidronaftalen-2-ol.

Info

Publication number
MX2011008868A
MX2011008868A MX2011008868A MX2011008868A MX2011008868A MX 2011008868 A MX2011008868 A MX 2011008868A MX 2011008868 A MX2011008868 A MX 2011008868A MX 2011008868 A MX2011008868 A MX 2011008868A MX 2011008868 A MX2011008868 A MX 2011008868A
Authority
MX
Mexico
Prior art keywords
cancer
tetrahydronaphthalen
derivatives
endometriosis
anxiety
Prior art date
Application number
MX2011008868A
Other languages
English (en)
Inventor
Herman Thijs Stock
Neeltje Miranda Teerhuis
Gerrit Herman Veeneman
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2011008868A publication Critical patent/MX2011008868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a derivados novedosos de tetrahidronaftalen-2-ol, a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia, en particular a su uso para la elaboración de un medicamento para la prevención o tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, cáncer de próstata, bochornos, ansiedad, depresión, cáncer de mama, carcinoma de tiroides medular, cáncer de ovario, enfermedad inflamatoria de intestino, artritis, endometriosis, y cáncer de colon.
MX2011008868A 2009-03-13 2010-03-12 Derivados de tetrahidronaftalen-2-ol. MX2011008868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155076 2009-03-13
PCT/EP2010/053167 WO2010103095A1 (en) 2009-03-13 2010-03-12 Tetrahydronaphthalen-2-ol derivatives

Publications (1)

Publication Number Publication Date
MX2011008868A true MX2011008868A (es) 2011-09-15

Family

ID=40886684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008868A MX2011008868A (es) 2009-03-13 2010-03-12 Derivados de tetrahidronaftalen-2-ol.

Country Status (15)

Country Link
EP (1) EP2406206B1 (es)
JP (1) JP5570535B2 (es)
KR (1) KR20110128790A (es)
CN (1) CN102272081B (es)
AR (1) AR075740A1 (es)
AU (1) AU2010223209B2 (es)
BR (1) BRPI1007505A2 (es)
CA (1) CA2748963C (es)
ES (1) ES2404344T3 (es)
IL (1) IL213262A0 (es)
MX (1) MX2011008868A (es)
NZ (1) NZ594085A (es)
TW (1) TW201043595A (es)
WO (1) WO2010103095A1 (es)
ZA (1) ZA201104279B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110746392B (zh) * 2019-10-31 2023-06-09 重庆医科大学 一类呋喃化合物在制备抗肿瘤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT388631B (de) 1985-04-16 1989-08-10 Siemens Ag Oesterreich Einrichtung zur steuerung des feldstromes von gleichstrommotoren
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
WO2001064665A1 (en) * 2000-03-01 2001-09-07 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
DK1268453T3 (da) * 2000-04-07 2006-10-23 Pfizer Prod Inc Östrogen agonist/antagonist metabolitter
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US7217734B2 (en) 2001-11-19 2007-05-15 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2006088716A1 (en) 2005-02-15 2006-08-24 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
CN101092363B (zh) * 2006-06-23 2010-08-18 浙江海正药业股份有限公司 芳基四氢萘类木脂素化合物及其制备方法和用途

Also Published As

Publication number Publication date
ES2404344T3 (es) 2013-05-27
TW201043595A (en) 2010-12-16
AU2010223209A1 (en) 2011-06-30
EP2406206B1 (en) 2013-01-30
CA2748963A1 (en) 2010-09-16
CN102272081B (zh) 2014-04-30
CA2748963C (en) 2017-03-28
NZ594085A (en) 2013-01-25
IL213262A0 (en) 2011-07-31
BRPI1007505A2 (pt) 2016-02-23
ZA201104279B (en) 2012-02-29
WO2010103095A1 (en) 2010-09-16
EP2406206A1 (en) 2012-01-18
KR20110128790A (ko) 2011-11-30
AU2010223209B2 (en) 2014-07-24
CN102272081A (zh) 2011-12-07
JP2012520265A (ja) 2012-09-06
JP5570535B2 (ja) 2014-08-13
AR075740A1 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
EP2276509A4 (en) PROOF AND TREATMENT OF PANCREAS, EGGS AND OTHER CARCINOMAS
BR112012018413A2 (pt) 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos.
EP1893196A4 (en) DIARYLHYDANTOIN CONNECTIONS
EP2506881C0 (en) COMBINATION OF RADIOIMMUNOTHERAPY AND ANTIBODY-DRUG CONJUGATES FOR BETTER CANCER THERAPY
EP2429574A4 (en) COMPOSITIONS AND METHODS OF TREATING BLOOD CANCER REGARDING SIRP-CD47 INTERACTION
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
NZ710729A (en) Amatoxin derivatives
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
EP2061327A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF IRRITATION, FAMILY ADENOMATOUS POLYPOSIS AND CANCER
IN2012MN02591A (es)
NZ630205A (en) Enhancer of zeste homolog 2 inhibitors
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
MY159375A (en) Combinatorial therapy
TN2012000188A1 (en) Novel antitumoral use of cabazitaxel
ZA201107879B (en) Composition for the treatment of prostate cancer
MY150407A (en) Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
IL216987A0 (en) Composition for the treatment of benign prostate hyperplasia
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
FI20125207L (fi) Fulvestrantti 500 mg annoksena pitkälle edenneen rintasyövän hoitoon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal